Please assess the completion status of the following clinical trial:

Trial Title: At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* UnitedHealthcare member~* confirmed COVID-19 positive~* located in an area where Bamlanivimab (LY3819253) is available for infusion~Exclusion Criteria:~* current (from first symptom report) hospitalization for COVID-19~* prior administration of Bamlanivimab or other COVID-19 therapies~* previous COVID-19 diagnosis~* prior receipt of a COVID-19 vaccine~* not authorized for patient use per the EUA

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Participants with COVID-19 (Type: EXPERIMENTAL): Participants testing positive for COVID-19 may be eligible to receive a one-time dose of bamlanivimab 700 mg, delivered via infusion through the vein, lasting around 60 minutes. This infusion will be done in-home and administered by a registered nurse.

Based on this trial design, predict the completion outcome and termination type (if applicable).